4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients.
Peter A. Fasching
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Walter Gumbrecht
Employment or Leadership Position - Siemens Healthcare Diagnostics
Tanja N Fehm
No relevant relationships to disclose
Lothar Haeberle
No relevant relationships to disclose
Mathias Muth
Employment or Leadership Position - Novartis
Daniel Sickert
Employment or Leadership Position - Siemens Healthcare Diagnostics
Michael Pugia
Employment or Leadership Position - Siemens Healthcare Diagnostics
Stock Ownership - Siemens Healthcare Diagnostics
Katja Friedrich
Employment or Leadership Position - Siemens Healthcare Diagnostics
Mark Matzas
Employment or Leadership Position - Siemens Healthcare Diagnostics
Diana Lueftner
Consultant or Advisory Role - Novartis
Matthias W. Beckmann
No relevant relationships to disclose
Peyman Hadji
Consultant or Advisory Role - Novartis
Julia Kreuzeder
Employment or Leadership Position - Novartis
Michael P Lux
Consultant or Advisory Role - Novartis
Wolfgang Janni
Consultant or Advisory Role - Novartis
Andreas Schneeweiss
Consultant or Advisory Role - Novartis
Erik Belleville
Consultant or Advisory Role - Novartis
Thomas Decker
No relevant relationships to disclose
Eva-Maria Grischke
No relevant relationships to disclose
Hans Tesch
Consultant or Advisory Role - Novartis